This is a StreetInsider.com Premium Only Page

(KDNY) – StreetInsider.com Reports

Aug 8, 2023 06:34 AM Wedbush Downgrades Chinook Therapeutics (KDNY) to Neutral

Aug 1, 2023 04:12 AM Wells Fargo Downgrades Chinook Therapeutics (KDNY) to Equal Weight

Jun 14, 2023 06:28 AM Evercore ISI Downgrades Chinook Therapeutics (KDNY) to In Line

Jun 13, 2023 06:42 AM Stifel Downgrades Chinook Therapeutics (KDNY) to Hold

Jun 13, 2023 06:07 AM H.C. Wainwright Downgrades Chinook Therapeutics (KDNY) to Neutral

Jun 13, 2023 06:03 AM SVB MoffettNathanson Downgrades Chinook Therapeutics (KDNY) to Market Perform

Jun 12, 2023 04:19 PM Stock market today: Dow closes higher on strength in tech ahead of Fed meeting

Jun 12, 2023 03:46 PM S&P 500 hits 13-month high as tech shines on bets Fed to skip hike later this week

Jun 12, 2023 11:43 AM Guggenheim Downgrades Chinook Therapeutics (KDNY) to Neutral

Jun 12, 2023 11:30 AM Bloom Burton & Co. Downgrades Chinook Therapeutics (KDNY) to Hold (3)

Jun 12, 2023 11:22 AM Cantor Fitzgerald Downgrades Chinook Therapeutics (KDNY) to Neutral

Jun 12, 2023 10:56 AM William Blair Downgrades Chinook Therapeutics (KDNY) to Market Perform

Jun 12, 2023 06:52 AM European stocks trade higher; UBS gains after completing Credit Suisse takeover

Jun 12, 2023 05:22 AM Chinook Therapeutics (KDNY) Acquired by Novartis AG (NVS) for $40/sh or $3.2B

Jun 12, 2023 01:23 AM Novartis buys Chinook for $3.5 billion in race to treat rare kidney disease

May 16, 2023 10:55 AM Chinook Therapeutics plunges as Muddy Waters alleges it 'systemically manipulated research findings'

May 16, 2023 10:04 AM Chinook Therapeutics (KDNY) options active as shares pull back 10%

May 16, 2023 10:02 AM Chinook Therapeutics (KDNY) Mentioned as Short at Muddy Waters

May 16, 2023 09:57 AM Chinook Therapeutics (KDNY) Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease (earlier)

May 10, 2023 06:47 AM Chinook Therapeutics (KDNY) PT Raised to $32 at H.C. Wainwright

May 9, 2023 04:48 PM Chinook Therapeutics, Inc. (KDNY) Misses Q1 EPS by 6c

Apr 13, 2023 08:05 AM Chinook Therapeutics (KDNY) Announces the Appointment of Robert W. Azelby to its Board of Directors

Apr 11, 2023 08:02 AM Chinook Therapeutics (KDNY) Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers

Mar 6, 2023 04:16 AM Piper Sandler Starts Chinook Therapeutics (KDNY) at Overweight

Mar 1, 2023 06:38 AM Guggenheim Starts Chinook Therapeutics (KDNY) at Buy

Feb 28, 2023 07:55 AM Chinook Therapeutics (KDNY) PT Raised to $34 at Oppenheimer

Feb 28, 2023 06:35 AM Chinook Therapeutics (KDNY) PT Lowered to $31 at H.C. Wainwright

Feb 21, 2023 07:25 AM Chinook Therapeutics (KDNY) PT Raised to $33 at Oppenheimer

Feb 15, 2023 08:03 AM Chinook Therapeutics (KDNY) Appoints Andrew Oxtoby as Chief Commercial Officer

Dec 22, 2022 07:51 AM Chinook Therapeutics (KDNY) PT Raised to $43 at Stifel

Dec 5, 2022 06:49 AM Wells Fargo Starts Chinook Therapeutics (KDNY) at Overweight

Nov 23, 2022 10:49 AM Chinook Therapeutics (KDNY) PT Raised to $33 at H.C. Wainwright

Nov 3, 2022 10:00 AM Chinook Therapeutics (KDNY) Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort

Aug 15, 2022 06:29 AM Chinook Therapeutics (KDNY) PT Raised to $32 at H.C. Wainwright

Jul 5, 2022 08:03 AM Chinook Therapeutics (KDNY) Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy

Jun 27, 2022 04:10 PM UPDATE: Stifel Starts Chinook Therapeutics (KDNY) at Buy

May 25, 2022 09:14 AM Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)

May 25, 2022 05:52 AM Chinook Therapeutics (KDNY) Prices $105M Public Offering at $14/sh

May 24, 2022 05:41 PM After-Hours Stock Movers 05/24: Wendy's Gains on Possible Peltz Deal, Nordstrom Up Following Earnings (more...)

May 24, 2022 04:03 PM Chinook Therapeutics (KDNY) Announces Proposed Stock Offering, Size not Disclosed

May 24, 2022 04:03 PM Chinook Therapeutics (KDNY) Files Mixed Shelf

May 23, 2022 07:48 AM Chinook Therapeutics (KDNY) PT Raised to $28 at Oppenheimer

May 23, 2022 06:27 AM Chinook Therapeutics (KDNY) PT Raised to $38 at Wedbush

May 23, 2022 06:12 AM Chinook Therapeutics (KDNY) PT Raised to $44 at SVB Leerink

May 20, 2022 10:28 AM Chinook Therapeutics (KDNY) Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort

May 19, 2022 05:40 AM Chinook Therapeutics (KDNY) Presents Updated Data from BION-1301 Phase 1/2 Trial

May 13, 2022 06:49 AM Chinook Therapeutics (KDNY) PT Raised to $30 at Wedbush

Mar 21, 2022 08:15 AM Chinook Therapeutics (KDNY) Appoints Mahesh Krishnan to its Board

Mar 17, 2022 04:01 PM Chinook Therapeutics (KDNY) Reports Q4; Provides Business Update

Dec 14, 2021 08:16 AM Chinook Therapeutics (KDNY) Granted Orphan Drug Designation in EU for Atrasentan for Treatment of Primary IgA Nephropathy